NCT06705504View on ClinicalTrials.gov

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

CompletedOBSERVATIONAL
Enrollment

435

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT06705504 - A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib | Biotech Hunter | Biotech Hunter